Key Takeaways
- Atomic Alchemy, Oklo’s subsidiary, obtained its inaugural NRC materials license for isotope handling, processing, and distribution at its Idaho facility.
- This regulatory approval unlocks the company’s first commercial sales opportunity from the Idaho Radiochemistry Laboratory, creating a fresh revenue channel for the currently pre-revenue enterprise.
- This license pertains to isotope operations only — Oklo’s advanced nuclear reactor projects remain pending NRC authorization before electricity sales can commence.
- Separately, Oklo formalized a partnership with the U.S. Department of Energy for its inaugural reactor development at Idaho National Laboratory.
- Shares climbed 4.6% during premarket hours before the company’s quarterly earnings announcement scheduled for Tuesday evening.
Oklo achieved a significant regulatory breakthrough on Tuesday, albeit with important context. The Nuclear Regulatory Commission granted its first-ever materials license — specifically to Atomic Alchemy, the wholly-owned subsidiary that Oklo brought into its portfolio in 2025.
This authorization permits Atomic Alchemy to accept, store, process, and supply isotopes from its Idaho Radiochemistry Laboratory located in Idaho Falls. The license covers handling up to 2 Curies of Ra-226, plus Co-60 and Am-241 for calibration applications.
These isotopes serve critical roles in medical treatments, scientific research, industrial manufacturing, and national defense. Oklo’s CEO Jacob DeWitte highlighted the market gap: “Demand for critical isotopes is rising, but U.S. supply remains limited.”
The commercial implications are tangible. Atomic Alchemy can now launch revenue-generating isotope sales from its Idaho operations, representing the first income-producing activity within Oklo’s corporate structure. The parent company hasn’t recorded revenue to date.
Crucial distinction: this license differs entirely from the reactor authorization investors have been monitoring. Oklo’s advanced fast reactor technology continues navigating the NRC approval pipeline. Until that authorization arrives, the company cannot commercialize electricity generation — its primary long-term business model.
Scope and Capabilities of the New License
The NRC issued this authorization following comprehensive evaluation procedures and physical inspection of the Idaho location. Atomic Alchemy’s strategy involves recovering dormant radium sources — materials historically classified as waste — and converting them into valuable feedstock for medical isotope manufacturing, including targeted alpha therapy applications.
The subsidiary has broader ambitions beyond this initial operation. Atomic Alchemy is engineering a multi-reactor isotope production facility featuring up to four Versatile Isotope Production Reactor (VIPR) units, each delivering approximately 15 MWth output capacity.
Tuesday delivered additional corporate news. Oklo revealed it had formalized an arrangement with the U.S. Department of Energy to facilitate design, construction, and operational phases of its first reactor at Idaho National Laboratory through the DOE’s Reactor Pilot Program.
Meta Partnership and Upcoming Earnings
Oklo has secured backing from a major technology company. The firm maintains a strategic alliance with Meta Platforms for developing a nuclear energy campus in southeastern Ohio. BofA Securities characterized this arrangement as “one of a few firm, binding partnerships today” within the emerging nuclear sector.
Shares advanced 4.6% in premarket activity Tuesday following the announcements. The company is set to release quarterly financial results after the closing bell that same day.
Oklo projects commercial nuclear power generation will begin in late 2027 or 2028.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
